Form 4: Edwards Lifesciences Executive Larry L. Wood Reports Stock and Option Grants

Larry L. Wood, Global President of TAVR & Surgical at Edwards Lifesciences, reports the acquisition of stock options and restricted stock units, as well as the disposition of shares to cover tax obligations.

Summary

• On May 7, 2024, Larry L. Wood, Global President TAVR & Surgical at Edwards Lifesciences, reported changes in beneficial ownership to the SEC.
• Wood acquired 8,725 shares of common stock and disposed of 695 shares to satisfy tax obligations at a price of $85.09 per share.
• Following these transactions, Wood directly owns 224,510.739 shares of common stock and indirectly owns 495.8781 shares through a 401(k).
• Wood also acquired options to purchase 51,700 shares of common stock at an exercise price of $85.84, which become exercisable in monthly installments starting June 7, 2024, and expire on May 6, 2031.
• Additionally, Wood was granted 8,725 performance-based restricted stock units that will vest on May 7, 2027, contingent on achieving certain performance goals over a three-year period.

Sentiment

Score: 7

Explanation: The document is neutral in tone, reporting standard executive compensation practices. The grants are a positive sign of incentivizing management, but the tax-related sale is a minor negative.

Positives

• The grant of stock options and restricted stock units aligns executive compensation with company performance and shareholder value.
• The vesting schedule of the options (monthly installments) encourages long-term commitment from the executive.
• The performance-based vesting of restricted stock units incentivizes the achievement of specific company goals.

Negatives

• The disposal of 695 shares, while for tax obligations, could be perceived negatively if not understood in context.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Edwards Lifesciences' stock.
• The vesting of the performance-based restricted stock units is contingent on achieving specific performance goals, which may not be met.
• Market conditions and industry trends could impact the value of the granted securities.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the options and restricted stock units suggest a long-term alignment of the executive's interests with the company's performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Edwards Lifesciences. It reflects standard practices for incentivizing and retaining key personnel in the medical device industry.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common compensation tools in the medical device industry, used by companies like Medtronic, Abbott, and Boston Scientific.
• The vesting schedules and performance-based criteria are generally aligned with industry norms for executive compensation packages.
• The amounts of stock and options granted are likely determined based on the executive's role, performance, and overall compensation strategy, which are typically benchmarked against peer companies.

Stakeholder Impact

• Shareholders may view the stock and option grants as a positive sign of aligning management's interests with company performance.
• Employees may see the grants as a reflection of the company's commitment to rewarding key personnel.
• The transactions have no direct impact on customers, suppliers, or creditors.

Key Dates